Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616694 · ClinicalTrials.gov registry record · Phase 4
Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy
A Phase 4 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
NCT00616694 is a Phase 4 study that has completed, run by Sanofi. The registered enrollment target is 248 participants.
The verdict
NCT00616694, a Phase 4 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
Study Summary
To evaluate the effect of subject knowledge of their disease status on persistence in subjects receiving Actonel 5 mg daily over a 12-month period for the prevention and treatment of GIO.
Interventions
- DRUG Actonel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2002-07 |
| Est. Completion | 2004-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616694
The ClinicalTrials.gov registry entry for NCT00616694 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Actonel is the first listed.
NCT00616694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00616694 about?
NCT00616694 is a clinical study titled "Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy". To evaluate the effect of subject knowledge of their disease status on persistence in subjects receiving Actonel 5 mg daily over a 12-month period for the prevention and treatment of GIO.
What is the current status of trial NCT00616694?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 2002-07. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00616694?
The interventions under investigation include: Actonel (DRUG).
Who is sponsoring clinical trial NCT00616694?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.